With all due respect, I wouldn't overestimate the oncologist's ability to keep up to date. My whole day job is hinged on analyzing where they struggle to keep up, and even the experts who bother to attend conferences and make the effort to educate themselves are often lacking in up-to-date knowledge.
It's even true in gynecologic oncology, where areas like ovarian cancer now have PARP inhibitors, but only about 20% of eligible patients receive them, or some such figure.
News 
Market Data 
Discover 
